|
4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE
|
DB07917 |
|
|
2-heptyl-4-hydroxyquinoline N-oxide
|
DB07918 |
|
|
7-METHOXY-1-METHYL-9H-BETA-CARBOLINE
|
DB07919 |
|
|
9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE
|
DB07940 |
|
|
PH-797804
|
DB07941 |
[PH-797804 has been investigated for the treatment of Osteoarthritis.] |
|
2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
|
DB07942 |
|
|
2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
|
DB07943 |
|
|
N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE
|
DB07944 |
|
|
5-(3-carbamoylbenzyl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-4-carboxylic acid
|
DB07945 |
|
|
N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide
|
DB07946 |
|
|
ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
|
DB07947 |
|
|
({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID
|
DB07949 |
|
|
Amdoxovir
|
DB06619 |
|
|
Cutamesine
|
DB06618 |
|
|
Bosutinib
|
DB06616 |
[Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.] |
|
Peramivir
|
DB06614 |
[Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.] |
|
Mepolizumab
|
DB06612 |
[Mepolizumab is a humanized IL-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells. It has a molecular weight of approximately 149 kDa. It was approved by the FDA in November, 2015 for the treatment of asthma under the brand name Nucala (marketed by GlaxoSmithKline). Mepolizumab has been investigated in the treatment of severe nasal polyposis, among numerous other conditions.] |
|
Pegsunercept
|
DB06611 |
[Pegsunercept is used for treating rheumatoid arthritis. Phase II clinical trials were completed in January 2010.] |
|
Omiganan
|
DB06610 |
[Omiganan has been investigated for the treatment of Mupirocin-resistant MRSA skin infections.] |
|
N-[1H-INDOL-3-YL-ACETYL]ASPARTIC ACID
|
DB07951 |
|
